Pds biotech announces multiple abstracts selected for presentation at the 2025 american society of clinical oncology (asco) annual meeting

Princeton, n.j., april 23, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that three abstracts on versamune® hpv (pds0101) have been accepted for presentation at the 2025 american society of clinical oncology (“asco”) annual meeting, taking place may 30-june 3, 2025, in chicago, illinois.
PDSB Ratings Summary
PDSB Quant Ranking